Alnylam Pharmaceuticals announced its new five‑year growth plan, "Alnylam 2030," on January 11, 2026. The strategy outlines a roadmap to expand the company’s product portfolio, increase manufacturing capacity, and strengthen its market position in key therapeutic areas, with a focus on ATTR amyloidosis.
The company’s preliminary full‑year 2025 net product revenue reached $2.987 billion, an 81% increase from $1.667 billion in 2024. The surge was driven by a 103% jump in TTR‑related sales, which rose to $2.487 billion, reflecting strong demand for its ATTR‑C and ATTR‑D indications. The 2025 growth pace is a continuation of the 2024 momentum, but the company notes that the 2025 guidance is already 71% higher than 2024, indicating a deceleration in the growth rate as the business scales.
Alnylam’s 2026 revenue guidance of $4.9 billion to $5.3 billion represents a 71% increase from 2025 and a 71% increase from 2024. The guidance is driven by a projected $4.4 billion to $4.7 billion in TTR franchise sales, an 83% rise from 2025, underscoring the centrality of ATTR amyloidosis to the company’s future growth. Management highlighted that the guidance reflects confidence in sustained demand for its ATTR portfolio and the ability to scale production to meet that demand.
The company is investing $250 million to expand its manufacturing facility in Norton, Massachusetts, to become the first fully dedicated siRNA enzymatic‑ligation production plant. The expansion is expected to be operational by late 2027, reducing production costs and increasing capacity for both commercial and pipeline products. This investment supports the company’s goal of a 30% non‑GAAP operating margin by 2030 and a 25% compound annual growth rate through 2030.
Alnylam’s pipeline now spans 10 tissue types and over 40 clinical programs, with a focus on rare and prevalent diseases such as hypertension, type 2 diabetes, and obesity. The company plans to allocate roughly 30% of revenue to R&D, reinforcing its commitment to innovation while maintaining profitability. CEO Yvonne Greenstreet emphasized that the past five years have been transformational, delivering on ambitious goals and establishing a strong foundation for future growth.
Analysts reacted with mixed sentiment. Some raised their outlooks in response to the robust 2026 guidance and the strong performance of the ATTR franchise, while others expressed caution over the commercial trajectory of Amvuttra in ATTR‑C, citing concerns about potential sales slowdown. The overall market reaction reflects a balance between confidence in Alnylam’s growth strategy and scrutiny of its key product launches.
Alnylam’s strategic shift signals a clear intent to accelerate growth and deepen its platform capabilities. The company’s focus on scaling operations, investing in manufacturing, and expanding its pipeline positions it to capture a larger share of the RNAi therapeutics market while maintaining a disciplined financial trajectory. The 2026 guidance and the 2030 strategy together suggest that Alnylam is poised to sustain high growth rates and profitability over the next decade.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.